FYB

Formycon
FYB

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
€386.85M
EV
€369.78M
Shares Outstanding
17.66M
Beta
0.80
Industry
Biotechnology

Wall Street View

Analyst Rating
OUTPERFORM
Analyst Target Price
Number of Analysts
8
P/E 2025E
122.21x
P/Revenue 2025E
7.13x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Formycon AG

gainify
FYB

Formycon AG

FYB

Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious retinal dise...

Sector

Healthcare

Industry

Biotechnology

CEO

Glombitza, Stefan

Employees

245

IPO Date

2011-01-04

Headquarters

Fraunhoferstrasse 15, Martinsried, Planegg, Bavaria, 82152, Germany

gainifypowered-by-sp
Socials
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on TrustpilotFollow us on YouTubeFind us on Google Maps

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.